Why Liquidia Stock Crashed 57% on Wednesday’s Patent Ruling Against Yutrepia
Liquidia (LQDA) stock crashed 57% on Wednesday, September 30, after a Delaware court ruled that Yutrepia infringes two valid claims of United Therapeutics’ ‘327 patent. Those claims cover treating pulmonary hypertension with interstitial lung disease (PH-ILD) using inhaled treprostinil, and the court struck down the rest.
United Therapeutics (UTHR) wants an injunction restricting Yutrepia’s availability, with a proposed judgment due within a week. Liquidia will ask the FDA to drop PH-ILD from the label and will appeal.
Raymond James analyst Ryan Deschner said the court’s denial of Liquidia’s motion to strike ownership evidence carried “negative readthrough to the final decision on the case.” It did. Liquidia stock now trades at $30, priced for a harsh remedy before any judge has written one.
Yutrepia’s patent loss erased 57% of Liquidia’s value in a day. Track the remedy ruling on TIKR for free →
TIKR Values Liquidia Stock at $59, Pricing In a Contained Patent Remedy
TIKR’s consensus mid-case model values Liquidia stock at $59 by December 2030, implying 95% total return from the current price of $30, or 17% annualized over 4.2 years.
A 17% annual return follows a 57% single-session collapse, which puts the $59 target far above where the ruling left the price.
TIKR’s consensus numbers support the $59 because no injunction exists yet and Liquidia has an appeal and a label fix already lined up.
A $59 target against a $30 stock is a 95% gap. See the full Liquidia model on TIKR for free →
So what is Liquidia Corporation stock actually worth?
TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what LQDA stock could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.
Value Liquidia Corporation for free→
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!
